Aflibercept is a VEGF-targeting biologic medicine marketed as Eylea and Zaltrap for ophthalmic and oncology indications. It is used for wet age-related macular degeneration and for metastatic colorectal cancer in specific combination regimens. It acts as a decoy receptor that inhibits VEGF signaling and angiogenesis.
Alvotech said it will release first-quarter 2026 financial results on May 6, 2026, and host a webcast with live Q&A on May 7. The company said five biosimilars are already approved and marketed, with nine disclosed candidates in development.
Ocular Therapeutix's experimental drug Axpaxli showed superior vision maintenance compared to Regeneron's Eylea in a late-stage wet AMD trial. Meanwhile, Ocugen reported 12-month data showing its gene therapy OCU410 reduced geographic atrophy lesions by 31%, though less than earlier interim results. Both companies are advancing toward regulatory submissions and further clinical development.
Zydus Lifesciences launched ANYRA, India's first indigenously developed aflibercept biosimilar, on February 19, 2026, following an agreement with Regeneron Pharmaceuticals and Bayer for multiple ophthalmic indications.
Ocular Therapeutix's Axpaxli outperformed low-dose Eylea in a Phase 3 trial for wet AMD, while Oculis Holding reported narrowed Q4 losses and expects Phase 3 trial readouts for OCS-01 in Q2 2026.
Samsung Bioepis reached settlement agreements with Regeneron and Bayer for its aflibercept biosimilar OPUVIZ, enabling U.S. launch in January 2027 and staged international rollout beginning early 2026.
Regeneron has consistently increased revenue over 35 years with blockbuster products like Dupixent and Eylea HD, while maintaining over a dozen phase 3 clinical trial candidates across multiple therapeutic areas.
Zydus Lifesciences launched ANYRA, India's first indigenous Aflibercept biosimilar for retinal conditions, and secured approval for a March 2026 day-one launch of generic semaglutide for diabetes and obesity treatment.
The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history, with $200-300 billion in yearly sales at risk through 2032 as major drugs lose exclusivity.
Samsung Bioepis and Regeneron reached a settlement allowing U.S. launch of Opuviz, an aflibercept biosimilar, in January 2027. The agreement resolves a patent dispute that began in late 2023.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05571267 |
Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD |
TERMINATED | PHASE2 |
| NCT04856397 |
Ozurdex in Suboptimal Diabetic Macular Edema Patients |
UNKNOWN | NA |
| NCT04739306 |
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema |
COMPLETED | PHASE3 |
| NCT04572698 |
A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD） |
UNKNOWN | PHASE3 |
| NCT04058535 |
Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD |
COMPLETED | PHASE1 |
| NCT03984110 |
One Year Trial Evaluating Safety of Ozurdex With Eylea |
COMPLETED | PHASE4 |
| NCT03629210 |
Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema |
WITHDRAWN | PHASE2 |
| NCT03610646 |
Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME) |
COMPLETED | PHASE3 |
| NCT03374670 |
ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) |
WITHDRAWN | PHASE2 |
| NCT02732899 |
Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD |
COMPLETED | PHASE2 |
